|
Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
CME Credit Available: 1 AMA PRA Category 1 CreditTM
Release Date: February 15, 2008
Date of Last Review/Update: February 3, 2009
Expiration Date: February 15, 2010
This Cases on the Web activity introduces a case with 4 clinical decision points, each focusing on an aspect of care for a patient who is requesting postexposure prophylaxis after possible sexual exposure to HIV. At each clinical decision point, learners should select the option that they believe is most sound and then read the presenter’s explanation of that option. Choosing the best option links the learner to an extended discussion of related medical findings, research-based evidence, and case management considerations.
To advance from one clinical decision point to the next, learners should click on the NEXT arrow at the base of each page that discusses the best clinical option.
After reviewing the case, learners may link to the continuing medical education (CME) posttest questions and the course evaluation, both of which must be completed and submitted to receive credit. Please see the posttest form and the evaluation form for further instructions.
On completion of this activity, the learner will be able to:
- Describe the appropriate use of postexposure prophylaxis after sexual exposure to HIV.
- Identify considerations for creating a strategy to avoid HIV infection in high-risk, HIV-seronegative patients.
- List the signs and symptoms of acute HIV seroconversion.
- Describe the differential diagnosis, appropriate diagnostic procedures, and considerations in the management of primary HIV seroconversion.
- Discuss what is known about preexposure prophylaxis and its current use.
The International AIDS Society–USA offers this state-of-the-art activity as part of a nationwide CME effort for HIV physicians on the evolving challenges of HIV disease. This activity examines relevant to the clinical management of patients who are at risk of exposure to HIV and who are requesting postexposure prophylaxis or preexposure prophylaxis for HIV.
This online CME activity is designed for physicians who are actively involved in HIV and AIDS care. Specifically, these activities have been designed for physicians who: - Have a solid, working knowledge of HIV disease management.
- Provide comprehensive or specialty care for at least 10 patients with HIV and AIDS or are involved in HIV and AIDS clinical trials or investigations.
- Have completed at least 10 hours of CME in the area of HIV and AIDS medicine in the past 2 years.
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care for people with HIV disease.
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME activity is offered from February 15, 2009 to February 15, 2010. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Nonphysician health care practitioners will receive a certificate of attendance.
Author
Raphael J. Landovitz, MD
Dr Landovitz is Assistant Professor of Medicine at the University of California Los Angeles (UCLA) and at the UCLA Center for Clinical AIDS Research and Education. He is the cochair of the intervention core of the UCLA Center for HIV Identification, Prevention, and Testing Services. His research interests are centered on the use of biomedical interventions as a tool in the prevention of HIV infection. He is currently medical director of a countywide effort to pilot postexposure prophylaxis programming in Los Angeles County.
Editor
Meg D. Newman, MD
Dr Newman is Associate Professor of Medicine at the University of California San Francisco and Director of the AIDS Education Program
at the San Francisco General Hospital. Dr Newman’s domains of interest include women and AIDS, HIV dermatology, hepatitis C virus and HIV coinfection, and HIV primary care.
In the interest of maintaining the independence of its continuing medical education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society–USA requires all persons with control of content (eg; authors, reviewers, Editorial Board members, and the staff of the Cases on the Web program) to disclose any financial interests that they (or their spouses or partners) have with commercial companies within the past 12 months.
Faculty
Dr Landovitz has served as a scientific advisor to Abbott Laboratories.
February, 2009 Update
Dr Landovitz has received honoraria for a single-company sponsored CME activity sponsored by Pfizer Inc.
Dr Newman has no relevant financial conflicts of interest to disclose.
Cases on the Web Editorial Board
The members of the Cases on the Web (COW) Editorial Board are volunteers and are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial interests with commercial companies within the past 12 months from the date of disclosure.
Michael S. Saag, MD — Editor-in-Chief
Professor of Medicine
The University of Alabama at Birmingham
Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Roche Laboratories, Tibotec Therapeutics, and Virco Lab, Inc. (Updated 02/01/10)
Meg D. Newman, MD — Coeditor
Associate Professor of Medicine
University of California San Francisco
Dr Newman has no relevant financial interests to disclose. (Updated 09/01/09)
Judith A. Aberg, MD
Associate Professor of Medicine
New York University School of Medicine
Dr Aberg has been a scientific advisor to Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. She participates in multicenter clinical trials from Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. Dr Aberg currently holds nonsalaried contracts for pending multicenter clinical trials with Adamas Pharmaceuticals, Inc, and Wyeth Pharmaceuticals. (Updated 10/06/09)
Roger J. Bedimo, MD, MS
Director, Infectious Disease Fellowship Training
University of Texas Southwestern Medical Center
Dr Bedimo has been a scientific advisor to Abbott Laboratories, Merck & Co, Inc, and Tibotec Therapeutics. He has received grants and research support from Abbott Laboratories, Merck & Co, Inc, and Tibotec Therapeutics. (Updated 10/08/09)
Marshall J. Glesby, MD, PhD
Associate Professor of Medicine and Public Health
Weill Medical College of Cornell University
Dr Glesby has no relevant financial interests to disclose. (Updated 09/01/09)
Paul E. Sax, MD
Associate Professor of Medicine
Harvard Medical School
Dr Sax received grants and research support from GlaxoSmithKline, Merck & Co, Inc, and Tibotec Therapeutics. He served as a consultant to or contributed to CME program materials for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. (Updated 09/14/09)
Staff of the Cases on the Web
Donna M. Jacobsen — Executive Director/President
Ms Jacobsen has no relevant financial interests to disclose. (Updated 09/01/09)
Mark F. Wales — Web Content Coordinator
Mr Wales has no relevant financial interests to disclose. (Updated 09/30/09)
IAS–USA Board of Directors
The nonstaff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their role in governing/overseeing the IAS–USA or its programs. Listed below are the IAS–USA Board of Directors and their financial interests with commercial companies within the last 12 months from the date of disclosure.
Constance A. Benson, MD
Professor of Medicine
University of California, San Diego
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline and Merck & Co, Inc, and has chaired data and safety monitoring boards for Johnson & Johnson Research Pty, Ltd (Australia) and Achillion Pharmaceuticals, Inc. (Updated 12/01/09)
Judith S. Currier, MD
Professor of Medicine
University of California, Los Angeles
Dr Currier has received research grants awarded to the University of California, Los Angeles from Merck & Co, Inc, Schering-Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, and has served on data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 10/09/09)
Carlos del Rio, MD
Professor of Medicine
Emory University
Dr del Rio has received research grants awarded to Emory University from the National Institutes of Health, the US Centers for Disease Control and Prevention, Merck & Co, Inc, and Sanofi Pasteur. He served as a consultant to, or received honoraria from, Bristol-Myers Squibb, Merck & Co, Inc, and Janssen-Cilag. (Updated 10/02/09)
Joel E. Gallant, MD, MPH
Professor of Medicine and Epidemiology
The Johns Hopkins University
Dr Gallant has served as a paid lecturer for Monogram Biosciences, Inc, and has been a consultant to Abbott Laboratories and Japan Tobacco. He has been a member of data and safety monitoring boards for Gilead Sciences, Inc, and Sangamo Biosciences, Inc and has been a member of scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck Serono, RAPID Pharmaceuticals AG, and Tibotec Therapeutics. Johns Hopkins University has been the recipient of research grants or contracts from Roche Laboratories for research conducted by Dr Gallant. (Updated 11/30/09)
Roy M. Gulick, MD, MPH
Professor of Medicine
Weill Medical College of Cornell University
Dr Gulick has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Virostatics. (Updated 11/25/09)
Douglas D. Richman, MD
Professor of Pathology and Medicine
University of California, San Diego
Dr Richman has been a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Chimerx, Gen-Probe, Inc, Gilead Sciences, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Merck & Co, Inc, Monogram Biosciences, Inc, Myriad Genetics, Inc, Pfizer Inc, and Theraclone Sciences. He has been on an endpoint adjudication committee for Schering-Plough Corp and has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of Chimerx and Idenix Pharmaceuticals, Inc, and a stock shareholder of Monogram Biosciences, Inc. (Updated: 10/09/09)
Michael S. Saag, MD — Editor-in-Chief
Professor of Medicine
The University of Alabama at Birmingham
Dr Saag has received grants and research support from and has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Roche Laboratories, Tibotec Therapeutics, and Virco Lab, Inc. (Updated 02/01/10)
Robert T. Schooley, MD
Professor of Medicine
University of California, San Diego
Dr Schooley has served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, LabCorp, Merck & Co, Inc, Pfizer Inc, TaiMed Biologics, and Vertex Pharmaceuticals, Inc. He has stock options for Achillion Pharmaceuticals, Inc and iTherX, Inc. (Updated 10/06/09)
Paul A. Volberding, MD
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California, San Francisco
Dr Volberding has been a member of the data and safety monitoring boards Merck & Co, Inc and TaiMed Biologics and on an endpoint adjudication committee for Schering-Plough Corp. He has provided paid legal consultation and expert testimony for commercial firms. Dr Volberding has served on scientific or clinical advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Pfizer Inc, and Tobira Therapeutics and he has been the recipient of service grants for, or held contracts from, GlaxoSmithKline Italy. (Updated 10/09/09)
This Cases on the Web activity is sponsored by the International AIDS Society–USA and was made possible through educational grants from the following commercial companies.
Grant Support: 2009 Update
Substantial Grant Support
Bristol-Myers Squibb
Gilead Sciences
Merck & Co, Inc
Pfizer Global Pharmaceuticals
Tibotec Therapeutics
Generous Grant Support
GlaxoSmithKline
Additional Grant Support
Roche Laboratories
Grant Support: 2008
Substantial Grant Support
Bristol-Myers Squibb
Tibotec Therapeutics
Abbott Laboratories
Gilead Sciences
Merck & Co, Inc
Pfizer Global Pharmaceuticals
Generous Grant Support
GlaxoSmithKline
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in Cases on the Web.
The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
If you have any questions about this Cases on the Web activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: info2009"at"iasusa.org
|
